For citations:
Barabanshchikova M.V., Morozova E.V., Vlasova Yu.Yu., Baykov V.V., Zubarovskaya L.S., Afanasyev B.V. Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis. The Scientific Notes of the Pavlov University. 2016;23(1):43-46. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-1-43-46
Email this article 